- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Novel Targeted Agents in Development, But Will Compete With Immunotherapy in RCC
November 5th 2016, 1:28am
Toni K. Choueiri, MD, dives into the ongoing research with volitinib, the competing yet complementary roles of targeted agents and immunotherapy, and the most important steps to take with biomarker research in the field of renal cell carcinoma.
Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC
November 5th 2016, 1:23am
Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).
Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer
November 5th 2016, 1:10am
The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.
Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer
November 4th 2016, 7:35pm
Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.
Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care
November 4th 2016, 7:31pm
Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.
Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer
October 11th 2016, 11:46pm
Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.
Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC
October 11th 2016, 11:41pm
Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.
Fulvestrant Bests Anastrozole in Phase III Breast Cancer Study
October 11th 2016, 2:50am
First-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with HR-positive advanced breast cancer.
Frontline Cabozantinib Bests Sunitinib in mRCC
October 11th 2016, 12:35am
Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.
Adjuvant Sunitinib Extends DFS in High-Risk RCC
October 10th 2016, 10:15am
Adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma.
Atezolizumab Significantly Extends Survival in NSCLC
October 10th 2016, 12:14am
Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.
Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC
October 9th 2016, 11:41pm
Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.
Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval
October 9th 2016, 11:24pm
Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.
Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer
October 9th 2016, 10:55pm
ESMO Congress: Gynecologic Cancers
Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.
Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC
October 9th 2016, 10:51pm
Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.
Frontline Pembrolizumab Data Is Practice Changing for NSCLC
October 9th 2016, 10:15am
Single-agent pembrolizumab improved overall and progression-free survival compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer who expressed PD-L1 on ≥50% of cells.
Antibody-Drug Conjugate Active in Pretreated Ovarian Cancer
October 9th 2016, 12:08am
ESMO Congress: Gynecologic Cancers
A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.
Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma
October 8th 2016, 11:30pm
Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the results of the phase III COMBI-v study in BRAF-mutant melanoma during an interview at the ESMO 2016 Congress.
Dr. Bruix on the Phase III RESORCE Trial in HCC
October 8th 2016, 11:26pm
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.
Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib
October 8th 2016, 10:14pm
The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.